All articles by Jennifer Smith-Parker
Jennifer C. Smith is an award-winning healthcare editor with 15+ years of expertise in the US and European pharmaceutical, regulatory and pricing/reimbursement sector. She carries in-depth knowledge on the clinical trials landscape and concerns that affect the pharma and biotech industry. She has moderated a number of conferences over the years, and led panel discussions on a wide-ranging set of topics. She has honed her skillet on the intersection of online journalism and business acumen, with a good understanding of SEO concepts and readership analytics to drive content strategy.
Jennifer Smith-Parker
Magazine: Looking back at two years of Covid-19
In this issue: We look at what the pandemic taught us about delivering essential vaccines and how it has burdened CAR-T production.
ESG in clinicals trials: What pharma needs to know
AI is main investment target, while 3D printing remains a largely untapped area.
LoA Update: BeiGene’s Phase III tislelizumab for esophageal squamous cell carcinoma sees 10-point jump for FDA approval forecast
As of 29 January, the US likelihood of approval (LoA) for BeiGene’s Phase III anti-PD-1 antibody for esophageal squamous cell carcinoma (ESCC) rose 10 points, according to GlobalData’s LoA data.
LoA Update: Agios’ Phase III mitapivat sulphate for pyruvate kinase deficiency sees 12-point rise in US approval prospects
As of 28 January, the likelihood of approval (LoA) by the FDA for Agios Pharmaceuticals’ Phase III drug for pyruvate kinase (PK) deficiency increased 12 points, according to GlobalData’s LoA data.